Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152 - COVAXIN biorxiv.org/content/10.110…
Several studies have demonstrated the reduction in the naturalisation efficacy of the SERA of naturally infected and individuals vaccinated with BBIP-CorV (1.6x) - Sinopharm, BNT162b2 (6.5X) - Pfizer, m-RNA1273 (8.6X) - Moderna, ChAdOx1 nCOV (86X) - COVIDSHIELD against B.1.351.
Reduced Naturalisation with the Vaccine Sera of BNT162b2 mRNA (7X) & one dose of ChAdOx1 nCov-19 was observed against B.1.617.2 Delta Variant.
Here, we have evaluated the neutralization potential of sera collected from COVID-19 recovered cases (n=20) and vaccinees with two doses of BBV152 (n=17) against B.1.351 and B.1.617.2 compared to the prototype B.1 (D614G) variant.
The finding of the study demonstrated a reduction in neutralization titers with sera of COVID-19 recovered cases(3.3-fold and 4.6-fold) and BBV152 vaccinees (3. 0 and 2.7 fold) against B.1.351 and B.1.617.2 respectively.
Although, there is reduction in neutralization titer, the whole-virion inactivated SARS-CoV-2 vaccine (BBV152) demonstrates protective response against VOC B.1351 and B.1.617.2.
Lastly broad epitope coverage of an inactivated virus vaccine BBV152 decreases the magnitude of reduced neutralisation against emerging variants of SARS-Cov-2.
While recent studies quote:
“Effectiveness was notably lower with B.1.617.2 (33.5%) than with B.1.1.7 (51 %) after 1 dose of AstraZeneca vaccine. The two- dose effectiveness against B.1.617.2 was estimated to be 60% and 88% for Astrazeneca and Pfizer vaccines, respectively.
Our neutralization experiments indicate that Astrazeneca vaccine-elicited antibodies are less potent against B.1.351 and B.1.617.2 than those induced by the Pfizer vaccine.”
The reduction of Neutralising Antibodies titers in COVAXIN against the mutant strains B.1.315 & B.1.617.2 was far lower eliciting better immunity compared to Pfizer or AstraZeneca COVIDSHIELD.
BBV152 showed neutralising of antibodies against B.1.315 variant (Beta) from Brazil & B.1.617.2 (Delta) to be 3 Folds & 2.6 Folds far less compared to Pfizer & AstraZeneca. Inactivated virus vaccine provides better protection against the mutants.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Summary of Various studies on Vaccines & on various strains of SARS-Cov-2 :
Original SARS-CoV-2 strain from Wuhan
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection - Nature Peer reviewed study of 17th May 2021
Nature Study on Original Wuhan Strain of SARS-CoV-2
>Novovax (Protein Sub Unit Vax Tops) - 98%
> Pfizer & Moderna - 95% after 2 Doses
> Sputnik - 95% 2 Doses
> COVAXIN - 80% 2 Doses
> AstraZeneca- 78% {2 doses after 8 weeks, post 12 weeks 90%]
> SINOVAC - 55% after 2 Doses
first dose of ChAdOx1 was found to be associated with small increased risks of ITP, with suggestive evidence of an increased risk of arterial thromboembolic and hemorrhagic events.
The attenuation of effect found in the SCCS analysis means that there is the potential for overestimation of the reported results, which might indicate the presence of some residual confounding or confounding by indication.
The SARS-CoV-2 high infectivity is due to the functional polybasic furin cleavage site in the S protein. How it was acquired is unknown. There are two challenges to face: (i) an evolutionary model, to fit the origin of the coronavirus; and (ii) a molecular mechanism for the site
Here we show genomic fingerprints which are specific of Pangolin-CoVs, Bat-SARS-like (CoVZC45, CoVZXC21), bat RatG13 and human SARS-CoV-2 coronaviruses.
Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine (COVAXIN) biorxiv.org/content/10.110…
The two-dose vaccine regimen significantly boosted the IgG titer and neutralizing efficacy against both B.1.1.28.2 and D614G variants compared to that seen with natural infection.
The study demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.1.1.28.2 variant in comparison with prototype D614G variant with sera of vaccine recipients and natural infection respectively.
Whereabouts of two scientists fired from Winnipeg virus lab for possible national-security issues shrouded in mystery headtopics.com/ca/whereabouts…
Four months before the couple was expelled from the lab, access-to-information documents show that Dr. Qiu played a key role in shipping two exceptionally virulent viruses – Ebola and Henipah – to China’s Wuhan facility.
The decision to grant access is made by the Public Health Agency of Canada,” CSIS spokesperson Keira Lawson said in an e-mail.Dr. Qiu’s name appears as a co-author on more than 120 scientific research papers between 2000 and 2021.
Are u a Virologist. Are u Biologist. Are u a Vaccineologists. I am an educated person who have read extensively read research papers on SARS COV 2 as well as Vaccine Trials and i state on TL various researches. As discussed o. space even doctors appreciated the effort put on TL.
Also one day u find study saying COVIDSHIELD better response than COVAXIN, other day there was Nature Medical Journal Article stating reverse. The other day we hear studies on how Spike Protein based Vaccines get neutralised on Mutants & need constant upgrades.
I share Various research on my TL. I was even advised by learned people to continue this trend & disseminate scientific information, while stating limitations, conflict of interest which is so stated in every Vaccine study to give a correct perspective. Rest is upto readers.